IDC MarketScape has named ZS a Leader in worldwide life science R&D strategic consulting services. According to the “IDC MarketScape: Worldwide Life Science R&D Strategic Consulting Services Vendor Assessment” (doc #US49950023, December 2023), ZS’s differentiators include its proven ability to accelerate time to value.
This IDC report focuses on how strategic consulting companies are maturing and innovating to deal with the rapidly evolving clients and industries they serve. Top-ranked companies show a zeal for innovation, a depth and breadth to their knowledge base and a cultural and strategic fit with their clients.
ZS partners with life sciences R&D teams to deliver transformative outcomes for patients through data, analytics, technology and end-to-end expertise across discovery, clinical development and compliance. ZS brings innovative strategies and thinking to niche areas such as the prioritization of use cases to drive investment decisions, the development of innovation score cards, clinical data valuation strategies, portfolio strategies, the development of clinical control towers and the ability to deliver long-term strategy along with short-term value, according to IDC.
“Organizations are seeking help building digital-by-design business strategies, reinventing business models and driving cultural change,” said Dr. Nimita Limaye, research VP, life science R&D strategy and technology, IDC. “They are seeking strategic consulting partners with deep domain and tech expertise, and more importantly, partners that can serve as their brain trust and that they can rely upon to lead the way.”
“We aim to speed up the typical six- to seven-year drug development timeline by optimizing clinical development processes and reducing study durations by 20% to 30%.”
Pratap Khedkar, CEO
ZS CEO Pratap Khedkar said the report highlights our strong digital, data and analytics capabilities and deep life sciences domain expertise. “At ZS, we bring a unique, end-to-end view of the drug development value chain that helps our pharma clients bridge medical, clinical and discovery solution areas to more quickly and cost-effectively launch new therapies,” said Khedkar. “We aim to speed up the typical six- to seven-year drug development timeline by optimizing clinical development processes and reducing study durations by 20% to 30%.”
Source: “IDC MarketScape: Worldwide Life Science R&D Strategic Consulting Services Vendor Assessment,” by Nimita Limaye (doc #US499500233, December 2023). Copyright IDC.
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
